Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Financial Results (Nov 12, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed November 12, 2024
Period End
November 12, 2024
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed November 12, 2024. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. reported its third-quarter 2024 financial results and business update on November 12, 2024.

Revenue was $2.7 milliona for the quarter and $216.0 million for the nine months ended September 30, 2024, versus $4.1 million and $7.6 million in the prior-year periods. The nine-month increase was primarily due to recognition of non-refundable upfront payments and service revenue under the Bayer and Kyowa Kirin exclusive license and collaboration agreements. Net loss attributable to common stockholders was $162.0 million ($0.86 per share) for the quarter and $270.7 million ($1.46 per share) for the nine months.

Operating costs and expenses rose, driven by selling, general and administrative expenses that the company attributes to commercialization readiness, and by higher research and development expenses for the nine months. Third-quarter operating costs and expenses were $194.5 millionb. The company ended the quarter with $405.7 million of cash, cash equivalents and short-term restricted cash.

Financing activity during the nine months included $434.0 millionc in net proceeds from a term loan under a credit facility with Blue Owl and $314.7 million in net proceeds from equity financings, offset by $473.4 million used to refinance its previous senior secured term loan, including prepayment fees and exit-related costs. Net cash used in operating activities was $325.4 million for the nine months. The company anticipates receiving a $500 million milestone payment upon FDA approval of acoramidis and $105 million in aggregate regulatory milestone payments upon approval in European and Japanese territories.

The key near-term catalyst is the November 29, 2024 PDUFA action date for acoramidis in ATTR-CM, for which a new drug application has been accepted. The company also expects three Phase 3 readouts in 2025, including the interim analysis of FORTIFY for BBP-418 in LGMD2I/R9, and it plans to share 42-month outcomes data from the acoramidis open-label extension at the American Heart Association Scientific Sessions on November 18.

Key Highlights

  1. Revenue of $2.7 million for Q3 2024 vs. $4.1 million a year earlier; nine-month revenue of $216.0 million vs. $7.6 million, driven by Bayer and Kyowa Kirin collaboration revenue.
  2. Net loss attributable to common stockholders of $162.0 million ($0.86 per share) for Q3 2024, and $270.7 million ($1.46 per share) for the nine months.
  3. Cash, cash equivalents and short-term restricted cash of $405.7 million as of September 30, 2024, compared with $392.6 million at December 31, 2023.
  4. Acoramidis for ATTR-CM has an NDA accepted by the FDA with a PDUFA action date of November 29, 2024; the company expects a $500 million milestone payment upon approval.
  5. Nine-month operating costs and expenses of $583.0 million, including $25.0 million of nonrecurring deal-related costs and an increase of $91.1 million in SG&A tied to commercialization readiness.
  6. Refinancing of the prior senior secured term loan cost $473.4 million including prepayment fees and exit-related costs, funded in part by a $434.0 million net term loan from Blue Owl.
  7. Three Phase 3 readouts expected in 2025, with FORTIFY (BBP-418 in LGMD2I/R9) enrollment completed and an interim analysis planned for 2025.

Frequently Asked Questions

  1. When is the FDA decision expected for acoramidis, and what does it mean financially?

    The PDUFA action date for acoramidis in ATTR-CM is November 29, 2024, and the late-cycle meeting with the FDA has been completed. The company anticipates a $500 million milestone payment upon FDA approval, plus $105 million in aggregate regulatory milestone payments upon approval in European and Japanese territories.

  2. Why did revenue change so significantly year over year?

    Nine-month revenue rose to $216.0 million from $7.6 million, primarily due to $205.3 million from recognition of non-refundable upfront payments and service revenue under the Bayer and Kyowa Kirin exclusive license and collaboration agreements. Third-quarter revenue declined to $2.7 million from $4.1 million, mainly because of services revenue under the Navire-BMS License Agreement, which terminated effective June 2024.

  3. What is driving higher operating costs?

    Nine-month operating costs and expenses increased by $145.5 million, primarily from a $91.1 million rise in selling, general and administrative expenses to support commercialization readiness, including marketing, advertising and salesforce buildup, and a $50.6 million rise in research and development expenses. Nine-month results also include $25.0 million of nonrecurring deal-related costs.

  4. How did the company's cash position change during the nine months?

    Cash, cash equivalents and short-term restricted cash increased by $13.1 million to $405.7 million. Inflows included $434.0 million in net term loan proceeds, $314.7 million in net equity financing proceeds, $63.2 million from sales of equity securities and $25.7 million in special dividends. These were offset by $473.4 million for refinancing the prior term loan and $325.4 million of net cash used in operating activities.

  5. What are the next key pipeline catalysts?

    The company plans to share 42-month outcomes data from the ATTRibute-CM open-label extension at the American Heart Association Scientific Sessions on November 18, 2024. It expects to complete enrollment of CALIBRATE (encaleret in ADH1) and PROPEL 3 (infigratinib in achondroplasia) in 2024, and expects three Phase 3 readouts in 2025, including the FORTIFY interim analysis for BBP-418.